stockrowFortrea Holdings Inc.
FTRE Healthcare Biotechnology
Fortrea Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 1.00% from fiscal 2024.
- Revenue
- −1.40%
- EPS
- +103.7%
- Free cash flow
- −34.0%
- Total debt
- −6.33%
Quarter to September 2026, against a year earlier
Follow FTRE
Alert me
Fortrea Holdings Inc. (FTRE) Book value per share
Fortrea Holdings Inc.'s book value per share at the end of fiscal 2025 was 6.2×, down 59.4% from 15.2× in fiscal 2024. At the end of the quarter to 30 September 2026 it was 5.6×. Over the past ten years it has ranged from 0.0× (fiscal 2021) to 37.6× (fiscal 2022); the current reading is higher than 50% of that period. Fortrea Holdings Inc. ranks 140th of 611 Biotechnology companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 6.2× | (59.41%) |
| FY2024 | 15.2× | (21.14%) |
| FY2023 | 19.3× | (48.72%) |
| FY2022 | 37.6× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Sep 2026 | 5.6× | 0.70% |
| Jun 2026 | 5.5× | (1.59%) |
| Mar 2026 | 5.6× | (9.07%) |
| Dec 2025 | 6.2× | (2.98%) |
| 15 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| HRMY Harmony Biosciences Holdings, Inc. compare | 18.4× |
| SRPT Sarepta Therapeutics, Inc. compare | 14.4× |
| FTRE Fortrea Holdings Inc. | 5.6× |
| VIR Vir Biotechnology, Inc. compare | 5.3× |
| IMNM Immunome, Inc. compare | 4.6× |
| TRAX First Tracks Biotherapeutics, Inc. compare | 4.2× |
| REPL Replimune Group, Inc. compare | 1.9× |
| ZYME Zymeworks Inc. compare | 1.1× |
| BHVN Biohaven Ltd. compare | −0.7× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))